SpineGuard Announces Its Full-Year 2023 Financial Results and Its First Quarter 2024 Sales
Regulatory News:
SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today its full-year 2023 financial results, for the financial year ending December 31, 2023, as approved by the Board of Directors on April 17, 2024, and its first quarter 2024 sales.
Q1 2024 revenue
€ thousands – IFRS (unaudited) |
2024 |
2023 |
Variance |
First Quarter |
1,351 |
1,271 |
+6.3% |
Lesen Sie auch
2023 Financial Results
€ thousands – IFRS audited |
2023 |
2022 |
Revenue |
4,313 |
5,600 |
Gross Margin |
3,379 |
4,715 |
Gross margin (% of revenue) |
78.3 % |
84.2 % |
Sales, distribution & marketing |
4,065 |
3,700 |
Administrative costs |
1,800 |
1,640 |
Research & Development |
1,434 |
901 |
Operating profit / (loss) |
-3,919 |
-1,526 |
Non-recurring operating costs |
-57 |
-135 |
Financial Result |
-225 |
-427 |
Income Tax |
18 |
-305 |
Net profit / (loss) |
-4,183 |
-2,393 |
EBITDA |
-3,544 |